- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Grants Expanded Approval of Siemens Healthineers Mammography Platform for Digital Breast Tomosynthesis
The inclusion of the 3D imaging technology PlatinumTomo in the Mammomat B.brilliant device reportedly enables clinicians to obtain 50-degree 3D images in less than five seconds.
Offering a variety of new features for improved efficiency and enhanced 3D breast imaging, the mammography platform Mammomat B.brilliant has garnered an expanded approval from the Food and Drug Administration (FDA).
Building upon the 50-degree wide-angle technology of its existing 3D mammography systems, Siemens Healthineers says the expanded approval for the device includes PlatinumTomo, which reduces blurring that commonly occurs with 3D imaging and allows one to obtain 50-degree 3D images in less than five seconds.
New features with the Mammomat B.brilliant platform include PlatinumTomo, which enables five-second acquisition of 50-degree 3D images, and UltraHD technology, which reduces metal artifacts and provides enhanced visualization of calcifications, according to Siemens Healthineers, the manufacturer of the device. (Image courtesy of Siemens Healthineers.)
Other new features with the Mammomat B.brilliant platform include a new X-ray tube, which includes adaptation of the flying focal spot technology from the company’s computed tomography (CT) scanners, according to Siemens Healthineers, the manufacturer of the Mammomat B.brilliant Device.
The company pointed out that the expanded approval also includes UltraHD technology for image reconstruction that facilitates enhanced calcification visualization, reduced metal artifacts and the availability of synthetic 2D images without exposing patients to additional radiation.
“This revolutionary system not only provides health-care institutions with significantly improved diagnostic capabilities but also addresses the critical need for patient and technologist comfort in breast cancer screening,” added Niral Patel, the vice president of X-ray products at Siemens Healthineers North America.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
